Merck Ranks 102nd in Trading Activity as Strategic Oncology Deal Sparks 1.27% Rally on 960-Million-Dollar Volume

, 2025, , . The pharmaceutical giant's performance was driven by a strategic partnership announcement with a biotech firm to co-develop a novel oncology therapy, . Analysts noted the collaboration could accelerate pipeline advancements, particularly in solid tumor treatments where Merck holds a strong R&D position.

Shareholder sentiment improved as the company reaffirmed its 2025 earnings guidance during a conference call, . The update contrasted with recent sector-wide concerns over pricing pressures, . Institutional investors increased their position size in the stock, reflecting confidence in its long-term growth trajectory despite short-term market volatility.

To run this back-test accurately I first need to clarify a few practical details so I can set up the data query and the portfolio engine correctly: 1. Market universe • Do you want all U.S.-listed common stocks (NYSE + NASDAQ + AMEX), or another exchange/universe? 2. Weighting scheme • Should the 500 selected names be equal-weighted each day, or value-weighted by their dollar volume? 3. Transaction assumptions • Any commission/slippage assumptions (e.g., 2 bp per trade), or can we ignore costs? 4. Rebalancing days • Trade every trading day at the next day’s open and exit at that day’s close (i.e., 1-day holding period), or open/close both at the close? 5. Benchmark • Would you like the results compared with a benchmark such as SPY? Once I have those details, I can pull the historical volume ranks, generate the daily trading signals, and run the back-test.